Pay in 4 interest-free payments of $5.07 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
WW promotes restriction and binging cycles common in people with disordered eating patterns
The future of obesity treatment with GLP-1 agonists will likely depend on continued therapeutic innovation and parallel advances in healthcare policy, delivery systems, and equity-focused implementation strategies
Time spent hoping patches will work is time not spent developing sustainable eating habits, increasing physical activity, or consulting healthcare providers about effective options
While nausea is common with this medication, its important to note any other symptoms, as they might indicate pancreatitis
Since the approval of semaglutide as Wegovy and tirzepatide as Zepbound, pharmaceutical companies and investors have been watching closely for the next therapy capable of matching or exceeding their clinical benchmarks
Generic approvals could influence broader access decisions as healthcare systems evaluate cost-effectiveness compared to brand-name alternatives like Mounjaro from Eli Lilly
